Hypothesis

Age‑related NAD+ decline does not merely reflect metabolic wear‑and‑tear; it actively tunes the activity of Activation‑Induced Cytidine Deaminase (AID) through SIRT1‑dependent deacetylation, thereby limiting both productive class‑switch recombination (CSR) and deleterious off‑target DNA damage in aged B cells. Restoring NAD+ alone will boost CSR but increase mutagenic risk unless SIRT1 activity is simultaneously modulated to preserve AID fidelity.

Mechanistic Basis

• NAD+ is a required co‑factor for the deacetylase SIRT1, which directly deacetylates AID at lysine residues governing its nuclear localization and catalytic efficiency ([2] links PARP‑driven NAD+ consumption to CSR defects).
• Inflammatory upregulation of CD38 in aged tissues drains NAD+, reducing SIRT1 activity ([1] shows CD38 inhibition raises tissue NAD+ in old animals).
• Hypoacetylated AID favors proper targeting to switch regions, whereas hyperacetylated AID exhibits promiscuous deamination, increasing off‑target mutations that can drive lymphoma.
• Thus, NAD+ depletion via CD38 acts as a rheostat: low NAD+ → low SIRT1 → hyperacetylated AID → restrained CSR but also reduced genomic instability; high NAD+ → high SIRT1 → hypomethylated AID → robust CSR but heightened mutagenesis risk.

Testable Predictions

1. CD38 inhibition in aged mice will increase AID acetylation, CSR efficiency, and off‑target mutagenesis (measured by switch circle formation and translocation sequencing).
2. Pharmacologic SIRT1 activation (e.g., SRT2104) will normalize AID acetylation, preserving CSR gains while suppressing off‑target damage.
3. Combined CD38 inhibition + SIRT1 activation will yield higher affinity antibody responses without elevating lymphoma incidence, whereas CD38 inhibition alone will raise lymphoma markers.
4. B‑cell‑specific SIRT1 knockout will mimic the effects of CD38 overexpression—reduced CSR despite high NAD+ levels.

Experimental Design

• Model: 20‑month‑old C57BL/6 mice; groups: (a) control, (b) CD38 inhibitor (78c), (c) SIRT1 activator, (d) CD38i + SIRT1 activator, (e) B‑cell‑specific SIRT1 KO + CD38i.
• Readouts (after 4 weeks):
  • Tissue NAD+ levels (LC‑MS).
  • SIRT1 activity (fluorometric deacetylation assay).
  • AID acetylation status (immunoprecipitation followed by anti‑acetyl‑lysine Western).
  • CSR efficiency (flow cytometry for IgG1+ B cells after LPS+IL‑4 stimulation).
  • Off‑target AID activity (high‑throughput sequencing of Myc, Bcl6, Pim1 loci).
  • Lymphoma surveillance (histopathology, serum β2‑microglobulin).
• Statistical plan: n=10 per group; ANOVA with Tukey post‑hoc; power >0.8 to detect 20% CSR change.

Falsifiability

If CD38 inhibition raises CSR without increasing AID acetylation or off‑target mutations, or if SIRT1 activation fails to curb mutagenesis despite restoring NAD+, the proposed NAD+–SIRT1–AID tuning mechanism would be refuted. Conversely, confirming the predicted biochemical and phenotypic shifts would support the hypothesis that the immune system deliberately lowers NAD+ to restrain AID‑driven genomic risk in aging.